Cytotoxic effect caspase activation dependent of a genetically engineered fusion protein with a CD154 peptide mimetic (OmpC-CD154_p) on B-NHL cell lines is mediated by the inhibition of bcl-6 and YY1 through MAPK p38 activation

References

• Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90:790–795.
   PubMed Web of Science ®Google Scholar
• Grover N, Park S. Novel targeted agents in Hodgkin and Non-Hodgkin lymphoma therapy. Pharmaceuticals (Basel). 2015;8:607–636.
   PubMedGoogle Scholar
• Voorzanger-Rousselot N, Blay JY. Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role. Leuk Lymphoma. 2004;45:1239–1245.
   PubMed Web of Science ®Google Scholar
• Briones J, Timmerman JM, Panicalli DL, et al. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst. 2003;95:548–555.
   PubMedGoogle Scholar
• Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10:1–13.
   PubMed Web of Science ®Google Scholar
• Buske C, Dreyling M, Unterhalt M, et al. Monoclonal antibody therapy for malignant lymphoma. Med Klin (Munich, Germany: 1983). 2005;100:14–24.
   PubMedGoogle Scholar
• Chen K, Huang J, Gong W, et al. CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system. Cell Mol Immunol. 2006;3:163–169.
   PubMed Web of Science ®Google Scholar
• Vega MI, Santos-Argumedo L, Huerta-Yepez S, et al. A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line. Immunology. 2003;110:206–216.
   PubMed Web of Science ®Google Scholar
• van den Oord JJ, Maes A, Stas M, et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol. 1996;149:1953–1961.
   PubMed Web of Science ®Google Scholar
• Cooke PW, James ND, Ganesan R, et al. CD40 expression in bladder cancer. J Pathol. 1999;188:38–43.
   PubMed Web of Science ®Google Scholar
• Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001;7:691–703.
   PubMed Web of Science ®Google Scholar
• Bussolati B, Russo S, Deambrosis I, et al. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. Int J Cancer. 2002;100:654–661.
   PubMed Web of Science ®Google Scholar
• Agathanggelou A, Niedobitek G, Chen R, et al. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol. 1995;147:1152–1160.
   PubMed Web of Science ®Google Scholar
• Altenburg A, Baldus SE, Smola H, et al. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol. 1999;162:4140–4147.
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG, Davies C, Knox PG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol. 2000;20:5503–5515.
   PubMed Web of Science ®Google Scholar
• Bugajska U, Georgopoulos NT, Southgate J, et al. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst. 2002;94:1381–1395.
   PubMed Web of Science ®Google Scholar
• Chan FKM, Chun HJ, Zheng L, et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351–2354.
   PubMed Web of Science ®Google Scholar
• Dadgostar H, Zarnegar B, Hoffmann A, et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci USA. 2002;99:1497–1502.
   PubMed Web of Science ®Google Scholar
• Zamaraev AV, Kopeina GS, Prokhorova EA, et al. Post-translational modification of caspases: the other side of apoptosis regulation. Trends Cell Biol. 2017;27:322–339.
   PubMed Web of Science ®Google Scholar
• Elmetwali T, Young LS, Palmer DH. CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. J Immunology. 2010;184:1111–1120.
   PubMed Web of Science ®Google Scholar
• Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432:635–639.
   PubMed Web of Science ®Google Scholar
• Lewis TS, McCormick RS, Stone IJ, et al. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia. 2011;25:1007–1016.
   PubMed Web of Science ®Google Scholar
• Batlle-López A, Cortiguera MG, Rosa-Garrido M, et al. Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus. Oncogene. 2015;34:246–256.
   PubMed Web of Science ®Google Scholar
• Klenova EM, Chernukhin IV, El-Kady A, et al. Functional phosphorylation sites in the C-terminal region of the multivalent multifunctional transcriptional factor CTCF. Mol Cell Biol. 2001;21:2221–2234.
   PubMed Web of Science ®Google Scholar
• Sayed M, Kim SO, Salh BS, et al. Stress-induced activation of protein kinase CK2 by direct interaction with p38 mitogen-activated protein kinase. J Biol Chem. 2000;275:16569–16573.
   PubMed Web of Science ®Google Scholar
• Batlle-Lopez A. Regulation of BCL6: p38 MAPK signalling and CTCF transcriptional regulation converge at exon 1 [dissertation]. London: Department of Medicine, Imperial College; 2010.
   Google Scholar
• Sanz-Moreno V, Casar B, Crespo P. p38alpha isoform Mxi2 binds to extracellular signal-regulated kinase 1 and 2 mitogen-activated protein kinase and regulates its nuclear activity by sustaining its phosphorylation levels. Mol Cell Biol. 2003;23:3079–3090.
   PubMed Web of Science ®Google Scholar
• Sui G, El Bachir A, Shi Y, et al. Yin Yang 1 is a negative regulator of p53. Cell. 2004;117:859–872.
   PubMed Web of Science ®Google Scholar
• Miles RR, Crockett DK, Lim MS, et al. Analysis of BCL6-interacting proteins by tandem mass spectrometry. Mol Cell Proteomics. 2005;4:1898–1909.
   PubMed Web of Science ®Google Scholar